Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor

Trial Profile

Phase II study of preliminary diagnostic performance of [68Ga]-NeoBOMB1 in adult patients with malignancies known to overexpress Gastrin Releasing Peptide Receptor

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs NeoBOMB1 (Primary)
  • Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
  • Focus Diagnostic use
  • Acronyms Neo-FIND
  • Sponsors Advanced Accelerator Applications
  • Most Recent Events

    • 12 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top